Inclusion body myositis

Seminars in Neurology

Volumn 32, Issue 3, 2012, Pages 237-245

  Dimachkie, Mazen M ^a   Barohn, Richard J ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

idiopathic inflammatory myopathies; inclusion body myositis; pathophysiology; polymyositis; prognosis; therapy

Indexed keywords

ALEMTUZUMAB; ANTINUCLEAR ANTIBODY; ARIMOCLOMOL; BETA1A INTERFERON; CONGO RED; CORTICOSTEROID; CREATINE KINASE; ETANERCEPT; FOLLISTATIN; HLA DR3 ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LITHIUM CHLORIDE; METHOTREXATE; OXANDROLONE; PITTSBURGH COMPOUND B; PREDNISONE; SIMVASTATIN; THYMOCYTE ANTIBODY;

ANTIGEN DETECTION; ARM WEAKNESS; ARTICLE; AUTOIMMUNE DISEASE; AUTOPHAGY; CORTICOSTEROID THERAPY; CYTOTOXIC T LYMPHOCYTE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DYSPHAGIA; ELECTRODIAGNOSIS; ENZYME BLOOD LEVEL; EXERCISE; FACE MUSCLE; FINGER; FLEXOR MUSCLE; FOOT DISEASE; FOREARM; GASTROCNEMIUS MUSCLE; GENE TRANSFER; HAND GRIP; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; LEG MUSCLE; LIMB WEAKNESS; MOTOR UNIT POTENTIAL; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE ISOMETRIC CONTRACTION; MUSCLE WEAKNESS; MYELOID DENDRITIC CELL; MYOPATHY; NECROTIZING MYOPATHY; PATHOGENESIS; PHYSIOTHERAPY; POLYMYOSITIS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUADRICEPS FEMORIS MUSCLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SARCOIDOSIS; SENSORY NEUROPATHY; SENSORY SYSTEM ELECTROPHYSIOLOGY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THENAR; THROMBOCYTOPENIA; TIBIALIS ANTERIOR MUSCLE; WRIST;

ELECTROPHYSIOLOGICAL PROCESSES; EXERCISE THERAPY; HUMANS; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; PHYSICAL THERAPY MODALITIES; PROGNOSIS;

EID: 84868235822     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0032-1329197     Document Type: Article

References (53)

1. Phillips B. A., Zilko P. J., Mastaglia F. L. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve: 2000; 23 6 970 972
2. Badrising U. A., Maat-Schieman M., van Duinen S. G., et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology: 2000; 55 9 1385 1387
3. Wilson F. C., Ytterberg S. R., St Sauver J. L., Reed A. M. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol: 2008; 35 3 445 447
4. Chahin N., Engel A. G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology: 2008; 70 6 418 424
5. Lotz B. P., Engel A. G., Nishino H., Stevens J. C., Litchy W. J. Inclusion body myositis. Observations in 40 patients. Brain: 1989; 112 Pt 3 727 747
6. Badrising U. A., Maat-Schieman M. L., van Houwelingen J. C., et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol: 2005; 252 12 1448 1454
7. Lindberg C., Persson L. I., Björkander J., Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand: 1994; 89 2 123 131
8. Sayers M. E., Chou S. M., Calabrese L. H. Inclusion body myositis: analysis of 32 cases. J Rheumatol: 1992; 19 9 1385 1389
9. Amato A. A., Gronseth G. S., Jackson C. E., et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol: 1996; 40 4 581 586
10. Barohn R. J., Amato A. A. Inclusion body myositis. Curr Treat Options Neurol: 2000; 2 1 7 12
11. Needham M., James I., Corbett A., et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry: 2008; 79 9 1056 1060
12. Larue S., Maisonobe T., Benveniste O., et al. Distal muscle involvement in granulomatous myositis can mimic inclusion body myositis. J Neurol Neurosurg Psychiatry: 2011; 82 6 674 677
13. Barohn R. J., Amato A. A., Sahenk Z., Kissel J. T., Mendell J. R. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology: 1995; 45 7 1302 1304
14. Hilton-Jones D., Miller A., Parton M., Holton J., Sewry C., Hanna M. G. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord: 2010; 20 2 142 147
15. Griggs R. C., Askanas V., DiMauro S., et al. Inclusion body myositis and myopathies. Ann Neurol: 1995; 38 5 705 713
16. Amato A. A., Barohn R. J. Idiopathic inflammatory myopathies. Neurol Clin: 1997; 15 3 615 648
17. Garlepp M. J., Laing B., Zilko P. J., Ollier W., Mastaglia F. L. HLA associations with inclusion body myositis. Clin Exp Immunol: 1994; 98 1 40 45
18. Degardin A., Morillon D., Lacour A., Cotten A., Vermersch P., Stojkovic T. Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol: 2010; 39 12 1219 1227
19. Cox F. M., Reijnierse M., van Rijswijk C. S., Wintzen A. R., Verschuuren J. J., Badrising U. A. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford): 2011; 50 6 1153 1161
20. Maetzler W., Reimold M., Schittenhelm J., et al. Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. J Neurol Neurosurg Psychiatry: 2011; 82 9 1060 1062
21. van der Meulen M. F., Hoogendijk J. E., Moons K. G., Veldman H., Badrising U. A., Wokke J. H. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord: 2001; 11 5 447 451
22. Greenberg S. A., Pinkus G. S., Amato A. A., Pinkus J. L. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve: 2007; 35 1 17 23
23. Greenberg S. A. Inclusion body myositis. Curr Opin Rheumatol: 2011; 23 6 574 578
24. Greenberg S. A., Sanoudou D., Haslett J. N., et al. Molecular profiles of inflammatory myopathies. Neurology: 2002; 59 8 1170 1182
25. Greenberg S. A., Bradshaw E. M., Pinkus J. L., et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology: 2005; 65 11 1782 1787
26. Salajegheh M., Lam T., Greenberg S. A. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS ONE: 2011; 6 5 e20266
27. Askanas V., Engel W. K. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology: 2006; 66 2 01 S39 S48
28. Askanas V., Engel W. K. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med: 2011; 40 4 Pt 2 e219 e235
29. Salajegheh M., Pinkus J. L., Nazareno R., Amato A. A., Parker K. C., Greenberg S. A. Nature of "Tauo" immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve: 2009; 40 4 520 528
30. Nogalska A., D'Agostino C., Engel W. K., Klein W. L., Askanas V. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol: 2010; 120 5 661 666
31. Amato A. A., Barohn R. J. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry: 2009; 80 11 1186 1193
32. Salajegheh M., Pinkus J. L., Taylor J. P., et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve: 2009; 40 1 19 31
33. Verma A., Bradley W. G., Ringel S. P. Treatment-responsive polymyositis transforming into inclusion body myositis. Neurology: 2008; P060 19
34. Benveniste O., Guiguet M., Freebody J., et al. Long-term observational study of sporadic inclusion body myositis. Brain: 2011; 134 Pt 11 3176 3184
35. Amato A. A., Barohn R. J., Jackson C. E., Pappert E. J., Sahenk Z., Kissel J. T. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology: 1994; 44 8 1516 1518
36. Dalakas M. C., Sonies B., Dambrosia J., Sekul E., Cupler E., Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology: 1997; 48 3 712 716
37. Dalakas M. C., Koffman B., Fujii M., Spector S., Sivakumar K., Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology: 2001; 56 3 323 327
38. Muscle Study Group Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurol (Tokyo): 2001; 57 1566 1570
39. Muscle Study Group Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurol (Tokyo): 2004; 63 718 720
40. Badrising U. A., Maat-Schieman M. L., Ferrari M. D., et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol: 2002; 51 3 369 372
41. Lindberg C., Trysberg E., Tarkowski A., Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology: 2003; 61 2 260 262
42. Rutkove S. B., Parker R. A., Nardin R. A., Connolly C. E., Felice K. J., Raynor E. M. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology: 2002; 58 7 1081 1087
43. Barohn R. J., Herbelin L., Kissel J. T., et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology: 2006; 66 2 01 S123 S124
44. Dalakas M. C., Rakocevic G., Schmidt J., et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain: 2009; 132 Pt 6 1536 1544
45. Sancricca C., Mora M., Ricci E., Tonali P. A., Mantegazza R., Mirabella M. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci: 2011; 32 5 841 847
46. Cox F. M., Titulaer M. J., Sont J. K., Wintzen A. R., Verschuuren J. J., Badrising U. A. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain: 2011; 134 Pt 11 3167 3175
47. Sekul E. A., Dalakas M. C. Inclusion body myositis: new concepts. Semin Neurol: 1993; 13 3 256 263
48. Arnardottir S., Alexanderson H., Lundberg I. E., Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med: 2003; 35 1 31 35
49. Johnson G. L., et al. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J Clin Neuromuscul Dis: 2007; 8 187 194
50. Johnson L. G., Collier K. E., Edwards D. J., et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis: 2009; 10 4 178 184
51. Takarada Y., Takazawa H., Sato Y., Takebayashi S., Tanaka Y., Ishii N. Effects of resistance exercise combined with moderate vascular occlusion on muscular function in humans. J Appl Physiol: 2000; 88 6 2097 2106
52. Wernbom M., Augustsson J., Raastad T. Ischemic strength training: a low-load alternative to heavy resistance exercise? Scand J Med Sci Sports: 2008; 18 4 401 416
53. Gualano B., Neves M. Jr, Lima F. R., et al. Resistance training with vascular occlusion in inclusion body myositis: a case study. Med Sci Sports Exerc: 2010; 42 2 250 254